Assessment of plasminogen activator inhibitor-1 in obese Egyptian children
Оценка ингибитора активатора плазминогена-1 у детей с ожирением в Египте
2020-01-06
SCID: 54.1/dm8trg48
Discuss with AI
HOMA-IRcardiovascular riskchildhood obesitymetabolic syndromeplasminogen activator inhibitor-1
Figures from the paper
Abstract (AI)
Abstract Background Plasminogen activator inhibitor-1 (PAI-1) is mainly produced in the liver and in the adipose tissue. Normal fibrin clearance mechanisms were found to be affected by high plasma PAI-1 levels and thus increases risk of thrombosis. The aim of the current study was to expound the childhood obesity effect on circulating PAI-1 and interpret the relation of PAI-1 to metabolic syndrome. This cross-sectional study was conducted on 43 obese children following in the Children Hospital and compared to 44 healthy sex- and age-matched controls. All recruited cohort are subjected to anthropometric measurements: weight, height, BMI, waist circumference, hip circumference, and skin fold thickness (biceps, triceps, and subscapular), and laboratory investigations in the form of lipid profile, fasting blood sugar, fasting insulin, insulin resistance estimated by HOMA-IR, and plasminogen activator inhibitor-1. Results The level of plasminogen activator inhibitor-1 in the obese group was significantly higher than that in the control group (47.98 ± 17.42 vs. 28.00 ± 11.35 respectively). PAI-1 showed positive significant correlation to anthropometric measurements: BMI (p = 0.000), weight (p = 0.000), biceps skin fold thickness (p = 0.04), triceps skin fold thickness (p = 0.4), and subscapular skin fold thickness (p = 0.04). Also, a significant positive correlation was found between PAI-1 and systolic (p = 0.000) and diastolic blood pressure (p = 0.04). Positive correlations were found between PAI-1 and cholesterol (p = 0.000), triglycerides (p = 0.02), LDL-c (p = 0.000), insulin (p = 0.000), and HOMA-IR (r = 0.5, p = 0.02). Conclusion Fat mass accumulation is related to high PAI-1 levels, which might in turn contribute to cardiovascular risk. Plasminogen Activator Inhibitor-1 is a good predictive test for metabolic syndrome in obese children.
Key Findings
1
Higher PAI-1 concentrations were significantly associated with increased systolic and diastolic blood pressure.
2
Obese children had significantly higher circulating PAI-1 levels than age- and sex-matched healthy controls (47.98 ± 17.42 vs. 28.00 ± 11.35).
3
PAI-1 levels positively correlated with obesity measures, including BMI, weight, and biceps and subscapular skinfold thickness.
4
PAI-1 positively correlated with cholesterol, triglycerides, LDL cholesterol, fasting insulin, and HOMA-IR, linking it to metabolic abnormalities.
5
The findings suggest that PAI-1 may predict metabolic syndrome and contribute to cardiovascular risk in obese children.
Research Object
obese Egyptian children
Research Subject
circulating plasminogen activator inhibitor-1 levels and their associations with anthropometric, cardiovascular, lipid, insulin-resistance, and metabolic-syndrome indicators
Publication Details
Publication Date
2020-01-06
Journal
Publisher
ISSN
Cited by
18
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest